Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
JPL plans to sell its entire 25.8% equity stake in Sofie for aggregate proceeds of about US$ 139.43 million
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
The company intends to respond to the two minor observations within the stipulated time
The Pregabalin capsules has a market size of ~US$248 mn per IQVIA
The registered capital of the newly founded company is € 50 million
The matter of Arbitration between Shilpa Medicare Limited and Celltrion towards supply and distribution agreement
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Growth team leads financing round in Cleveland Diagnostics; company to advance novel blood-based diagnostic technology to improve and lower costs for patients with cancer
Subscribe To Our Newsletter & Stay Updated
